Xuebijing Combined Hemoperfusion Efficacy In Patients With Early Application Of Paraquat Poisoning Pulmonary Fibrosis

Objective Because pesticide paraquat(PQ) component characteristics and chemical structure, resulting in human lung pesticide paraquat high uptake rate, high density distribution, high affinity and high savings rate characteristics, so the pesticide paraquat lung damage is most sensitive one of organs. Clinically breathing irreversible pulmonary fibrosis(PF) caused by respiratory failure(RF) for paraquat poisoning after the most serious and deadly disease, the treatment of one of the most intractable difficulties in the clinical setting, and therefore seek new combination treatment strategies are several ways to reduce the mortality rate of paraquat cause pulmonary fibrosis, reduce the incidence and severity of pulmonary fibrosis is a matter of current clinical close attention, this experiment aims for early use of Xuebijing combined hemoperfusion therapy in patients with paraquat poisoning alone give hemoperfusion(HP) treatment in patients with lung continuous high-resolution CT(HRCT) in contrast, the blood will investigate the net effect of paraquat poisoning treatment of patients with pulmonary fibrosis.Methods Select 102 cases of paraquat poisoning patients, according to the date of admission were randomly divided into two groups, Xuebijing combined hemoperfusion group(observation group), a simple blood perfusion group(control group),51 cases. Both groups were routinely paraquat poisoning emergency treatment, includingmethylprednisolone sodium succinate(MPSS) and cyclophosphamide(CTX) pulse therapy, the observation group in successive hemoperfusion(admission after 1 blood perfusion within h, hemoperfusion blood flow is set at 160 ~ 220 ml / min, once a day, every perfusion were 2.5h, continuous perfusion 7d, as the case may be added to 9d) on the basis of joint Xuebijing injection infusion therapy(Xuebijing injection 50 ml + saline 100 ml, 8h / times for 14d), the control group only received treatment early hemoperfusion, did not give Xuebijing intravenous injection therapy. Respectively, 3 days 1 week, 2 weeks and 4 weeks, the four periods patient survival statistics, the 3days, 4weeks, the two time periods were compared in patients with pulmonary fibrosis incidence, and the extent of the occurrence of the two groups were compared the 3 days 1 week, 2 weeks and 4 weeks of the four periods of pulmonary fibrosis.Results Observation group and control group patient survival when only the 4 weeks were 64.70% and 45.10%, survival was statistically significant(P <0.05). The 3 days were observed in lung fibrosis was 56.52%, 51.51% for the 4 weeks, the 3 days in the control group was 68.18%, 78.26% for the 4 weeks. The 4 weeks, fibrosis of the observation group was significantly better than the control group(P <0.05). Observation group only the 3 days to the 1 week, there is a significant degree of fibrosis exacerbation(P <0.05), each group with previous comparative fibrosis were significantly heavier(P <0.05) measurements; while in the second an fourth, pulmonary fibrosis has significant difference(P <0.05).Conclusion Xuebijing combined hemoperfusion make early application of paraquat poisoning patients improved survival, incidence and extent of pulmonary fibrosis were more substantial control, suitable for clinical adoption and use.